Non-Hodgkin Lymphoma

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy showed encouraging early efficacy among heavily pretreated patients with CD19-positive non-Hodgkin lymphoma, according to study results.

NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Patients recently treated with bendamustine had significantly lower response rates to subsequent chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, data presented at ASH Annual Meeting and Exposition showed.

NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

The treatment landscape for relapsed or refractory indolent non-Hodgkin lymphoma continues to shift from chemoimmunotherapy to targeted treatments, according to a speaker at Chemotherapy Foundation Symposium.

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.

Oncologists who treat non-Hodgkin lymphoma have increasingly become reliant on targeted treatment, with several new agents receiving FDA approval within the past 5 years.

The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.